TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results

Benzinga Logo Benzinga By Prnewswire
Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results

Soligenix reported a net loss of $2.5 million in Q3 2025, with ongoing clinical trials for HyBryte™ in cutaneous T-cell lymphoma and continued development of rare disease treatments. The company maintains approximately $10.5 million in cash and is focused on strategic milestones through 2026.

Insights
GOOG   positive

Primarily driven by Google Search revenue, introduced AI Search Overviews, survived potential monopoly breakup, and has stable core business


SNGX   neutral

The company reported a financial loss but is progressing with clinical trials, maintaining a strategic focus on product development and potential commercialization. The neutral sentiment reflects ongoing development without significant positive or negative breakthroughs.